[ClearPoint Neuro First Quarter 2025 Results](index=1&type=section&id=ClearPoint%20Neuro%20First%20Quarter%202025%20Results) [First Quarter 2025 Highlights](index=1&type=section&id=First%20Quarter%202025%20Highlights) ClearPoint Neuro achieved record Q1 2025 revenue of $8.5 million, an 11% increase, driven by a 104% surge in consumable products and strategic advancements Q1 2025 Key Performance Indicators | Metric | Q1 2025 | Change (YoY) | | :--- | :--- | :--- | | Total Revenue | $8.5 million | +11% | | Total Consumable Product Revenue | $5.3 million | +104% | | Cash and Cash Equivalents (as of Mar 31) | $12.4 million | N/A | - The CEO highlighted that the company is entering a "Fast Forward phase," with foundational investments in biopharma partnerships, operating room navigation, and laser therapy now yielding significant growth[3](index=3&type=chunk) - The company secured a long-term credit facility and an equity investment from Oberland Capital, enhancing balance sheet flexibility to achieve strategic goals[3](index=3&type=chunk) - Received FDA Clearance for the ClearPoint 3.0 Software, which is now in Full Market Release and contributing to revenue and case volume growth[4](index=4&type=chunk) [Financial Results – Quarter Ended March 31, 2025](index=2&type=section&id=Financial%20Results%20%E2%80%93%20Quarter%20Ended%20March%2031%2C%202025) Q1 2025 saw 11% revenue growth to $8.5 million and improved gross margin to 60%, but operating expenses rose 29% to $11.3 million, widening the operating loss to $6.2 million [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Revenue growth was driven by a 70% increase in Neurosurgery navigation and therapy sales and a 9% rise in Biologics and drug delivery, while Capital equipment revenue declined 63% Q1 Revenue Breakdown (in millions) | Revenue Segment | Q1 2025 | Q1 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | **Total Revenue** | **$8.5** | **$7.6** | **+11%** | | Biologics and Drug Delivery | $4.7 | $4.3 | +9% | | Neurosurgery Navigation and Therapy | $3.3 | $1.9 | +70% | | Capital Equipment and Software | $0.5 | $1.4 | -63% | - The increase in Neurosurgery revenue was driven by higher sales for new product offerings and an expanded customer base[8](index=8&type=chunk) - The decrease in Capital equipment revenue was primarily attributed to the timing of installations[9](index=9&type=chunk) [Profitability and Expenses](index=2&type=section&id=Profitability%20and%20Expenses) Gross margin improved to 60%, but operating expenses increased 29% to $11.3 million due to higher personnel and R&D costs, resulting in a net loss of $6.0 million Q1 Profitability Metrics (in millions, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Gross Profit | $5.1 | $4.5 | | Gross Margin | 60% | 59% | | Operating Expenses | $11.3 | $8.7 | | Operating Loss | ($6.2) | ($4.2) | | Net Loss | ($6.0) | ($4.1) | | Net Loss Per Share | ($0.22) | ($0.16) | - The **29% increase in operating expenses** was mainly due to higher personnel-related costs, increased product development, a higher allowance for credit losses, and greater professional and regulatory fees[11](index=11&type=chunk) [Financial Position](index=2&type=section&id=Financial%20Position) Cash and cash equivalents decreased to $12.4 million by March 31, 2025, primarily due to $6.2 million in cash used for operating activities Cash and Cash Equivalents (in millions) | Date | Amount | | :--- | :--- | | March 31, 2025 | $12.4 | | December 31, 2024 | $20.1 | - The decrease in cash was driven by **$6.2 million used in operating activities** and **$1.3 million for tax payments** on equity awards[12](index=12&type=chunk) [Business Outlook](index=2&type=section&id=Business%20Outlook) The company reaffirmed its full-year 2025 revenue guidance, projecting total revenue between $36.0 million and $41.0 million - Full year 2025 revenue outlook is reaffirmed to be between **$36.0 million and $41.0 million**[5](index=5&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) Unaudited consolidated financial statements for Q1 2025 show a net loss of $6.0 million, total assets of $30.1 million, and a $7.7 million net decrease in cash [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 revenue was $8.5 million, resulting in a net loss of $6.0 million, or ($0.22) per share, compared to a $4.1 million loss in Q1 2024 Consolidated Statements of Operations (Unaudited, in thousands, except per share data) | | For the Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | **Total revenue** | **$8,485** | **$7,639** | | Gross profit | $5,132 | $4,525 | | Operating loss | $(6,163) | $(4,216) | | **Net loss** | **$(6,026)** | **$(4,146)** | | **Basic and diluted net loss per share** | **$(0.22)** | **$(0.16)** | | Weighted average shares outstanding | 27,718,918 | 25,452,096 | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets were $30.1 million, down from $39.2 million, with total liabilities at $10.1 million and equity at $20.0 million Consolidated Balance Sheet Highlights (Unaudited, in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,387 | $20,104 | | Total current assets | $24,214 | $33,363 | | **Total assets** | **$30,070** | **$39,189** | | Total current liabilities | $6,866 | $10,353 | | **Total liabilities** | **$10,083** | **$13,800** | | **Total stockholders' equity** | **$19,987** | **$25,389** | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 saw $6.2 million net cash used in operating activities, $0.2 million in investing, and $1.4 million in financing, leading to a $7.7 million net decrease in cash Consolidated Statement of Cash Flows Highlights (Unaudited, in thousands) | | For the Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | Net cash flows from operating activities | $(6,172) | $(3,840) | | Net cash flows from investing activities | $(183) | $— | | Net cash flows from financing activities | $(1,362) | $16,053 | | **Net change in cash and cash equivalents** | **$(7,717)** | **$12,213** | | Cash and cash equivalents, end of period | $12,387 | $35,353 |

Group 1 - ClearPoint Neuro, Inc. (CLPT) shares have increased by 18.2% over the past four weeks, closing at $13.64, with a mean price target of $27.67 indicating a potential upside of 102.9% [1] - The average price targets range from a low of $25 to a high of $30, with a standard deviation of $2.52, suggesting a potential increase of 83.3% to 119.9% from the current price level [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, indicating a positive outlook for CLPT [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - CLPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movements [10][13]

Group 1 - ClearPoint's share price has been volatile, but there is a steady flow of positive news regarding its business fundamentals [1] - Richard Durant leads Narweena, an asset manager focused on identifying market dislocations due to poor long-term business prospects understanding [1] - Narweena aims for excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] Group 2 - Narweena's research emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] - The firm focuses on smaller cap stocks and markets where competitive advantages are not immediately apparent [1] - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, contrasting with past trends [1] Group 3 - Many industries may face stagnation or secular decline, potentially improving business performance due to reduced competition [1] - Other businesses may encounter rising costs and diseconomies of scale, affecting their performance negatively [1] - The economy is increasingly dominated by asset-light businesses, leading to a declining need for infrastructure investments over time [1] Group 4 - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] - Richard Durant holds undergraduate degrees in engineering and finance and an MBA, and has passed the CFA exams [1]

Group 1 - ClearPoint's fourth quarter results were somewhat soft, which is not surprising given that many of the company's growth initiatives are still ramping [1] - Guidance for ClearPoint was also weak, partly due to the timing of events [1] Group 2 - Narweena, an asset manager led by Richard Durant, focuses on finding market dislocations resulting from a poor understanding of long-term business prospects [1] - Narweena believes excess risk-adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry [1] - The research process at Narweena is centered on company and industry fundamentals to uncover unique insights [1] Group 3 - Narweena has a high risk appetite and a long-term investment horizon, targeting deeply undervalued stocks, particularly in smaller cap stocks and markets with less obvious competitive advantages [1] - The firm anticipates that an aging population with low growth and stagnating productivity will create new investment opportunities [1] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 4 - There is a trend of increasing dominance of asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] Group 5 - Richard Durant holds undergraduate degrees in engineering and finance from the University of Adelaide and an MBA from Nanyang Technological University [1] - Durant has passed the CFA exams, indicating a strong background in finance [1]

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings. Welcome to ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2024 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Opera ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company has ...

Product Development and Innovation - The ClearPoint system is an integrated system for neurosurgical applications, with over 90 centers globally utilizing its technology[24]. - The ClearPoint Prism Neuro Laser Therapy System was commercialized in 2022, developed and manufactured by CLS, with exclusive global rights for neuro applications[28]. - The SmartFrame Array Neuro Navigation System was launched in 2021, allowing for operating room placement of the ClearPoint system[27]. - In 2022, the ClearPoint Maestro Brain Model software received FDA approval, automating the identification and quantification of brain structures in MRI images[36]. - The ClearPoint Prism Neuro Laser Therapy System is indicated for soft tissue necrosis or coagulation under 3.0T MRI guidance, enhancing treatment precision[37]. - The SmartFlow cannula received 510(k) clearance for various applications, including the injection of Cytarabine and removal of cerebrospinal fluid, and was granted De Novo marketing authorization for AADC deficiency treatment[40]. - The SmartFrame OR Stereotactic System obtained 510(k) clearance in 2024, intended for stereotactic guidance in neurological procedures[42]. - The ClearPoint system received 510(k) clearance from the FDA for general neurosurgical procedures, allowing marketing in the U.S. and similar approvals in the EU, UK, Israel, Taiwan, Turkey, and Brazil[39]. - The SmartFlow cannula was granted De Novo marketing authorization in 2024 for AADC deficiency treatment, indicating a significant advancement in product offerings[44]. - The company has focused on developing its intellectual property portfolio and commercial applications since its inception in 1998[24]. Market Potential and Revenue - The market potential for the biologics and drug delivery segment is estimated to be approximately $7 billion, dependent on maintaining relationships with pharmaceutical customers[30]. - The company estimates over 140,000 potential neurosurgical procedures annually in the U.S. where ClearPoint products could be utilized[44]. - The ClearPoint business model focuses on high-margin revenue from disposable product sales, with reusable components sold at lower margins to secure hospital installations[45]. - Approximately 31% of neurosurgery navigation disposable product revenues in 2024 came from the five largest hospital customers[52]. - The company has commercial relationships with over 60 pharma/biotech partners, contributing to its biologics and drug delivery revenues[53]. - ClearPoint's revenue from preclinical development services has been growing significantly since 2021, contributing to its overall business[29]. Regulatory Compliance and Challenges - The company is subject to extensive regulation by the FDA, which includes premarket clearance and approval requirements for its medical devices[73]. - The company must comply with stringent quality management system regulations (QMSR) to maintain compliance with FDA and other regulations[92]. - The company is required to report any incidents involving its products that may have caused or contributed to serious injuries or deaths[89]. - The company faces potential enforcement actions from regulatory authorities for non-compliance, which could result in significant penalties[94]. - The company must navigate varying international regulations for medical device approvals, which can differ substantially from U.S. requirements[94]. - The Medical Devices Regulation (Regulation 2017/745) went into effect in May 2021, establishing a uniform regulatory framework across the EU for medical devices[101]. Competition and Market Position - The company faces significant competition from larger firms such as Medtronic and Brainlab in the medical device industry for neurosurgical applications[71]. - The medical device industry is highly competitive, with significant competition from companies like Monteris Medical, Medtronic, and others offering similar neurosurgical devices[71]. - The company focuses on image-guided drug delivery, facing competition from firms like Brainlab and Renishaw, which have greater resources[72]. Partnerships and Collaborations - The company has over 60 partners in pharma/biotech and academic sectors involved in trials for gene and cell therapies[30]. - The company entered into a multi-year license agreement with UCB in March 2023 for drug delivery platforms related to UCB's gene therapy portfolio, with success-based milestone fees[63]. - The company has expanded its collaboration with Philips to include additional technology for CT imaging and subnuclei segmentation in 2023[62]. - The company entered into a new license agreement with UCSF in 2023 to develop a radially branching cellular delivery device, committing to pay royalties based on future sales[66]. - The company has several software license arrangements for products like ClearPoint Software, committing to pay royalties for each copy sold or loaned[68]. Financial Performance and Employee Management - The company has incurred losses since inception and may continue to do so, indicating potential challenges in achieving profitability[23]. - The reliance on single-source suppliers poses risks to meeting product demand and could impact revenue[21]. - The company had 115 full-time employees as of February 18, 2025, with no employees covered by collective bargaining agreements[137]. - The company emphasizes cultural fit and energy in recruiting, aiming to provide market-based compensation to retain employees[137]. - New employees receive industry-relevant compliance training and are introduced to the company's Code of Business Conduct and Ethics[137].

Revenue Growth - Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared to Q4 2023[4] - Full year 2024 revenue reached $31.4 million, representing a 31% increase over 2023, marking the tenth consecutive year of growth[4] - Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year 2024[4] - Biologics and drug delivery revenue increased 27% to $17.3 million for the year ended December 31, 2024[8] - Neurosurgery navigation and therapy revenue increased 21% to $10.3 million for the year ended December 31, 2024[9] - Capital equipment and software revenue increased 107% to $3.8 million for the year ended December 31, 2024[10] - The company estimates 2025 revenue to be between $36.0 million and $41.0 million, representing growth between 15% and 31%[6] Operational Efficiency - Quarterly operational cash burn was $1.2 million, totaling $9.0 million for 2024, a reduction of 35% compared to 2023[4] - Achieved a gross margin of 61% for 2024, up from 57% in 2023[11] - Net cash flows from operating activities improved from $(13,720) million in 2023 to $(8,950) million in 2024, a reduction in cash outflow of approximately 34%[29] - Cash paid for interest decreased from $743 million in 2023 to $480 million in 2024, a reduction of approximately 35%[29] Asset and Liability Management - Total assets decreased from $42,661 million in 2023 to $39,189 million in 2024, a decline of approximately 8.7%[27] - Total current liabilities increased significantly from $7,430 million in 2023 to $10,353 million in 2024, an increase of approximately 39%[27] - Cash and cash equivalents decreased from $23,140 million in 2023 to $20,104 million in 2024, a decline of about 13%[29] - Accounts receivable increased from $3,211 million in 2023 to $4,713 million in 2024, an increase of approximately 47%[27] - Inventory decreased from $7,911 million in 2023 to $6,863 million in 2024, a decline of about 13.2%[27] Equity and Financing - Total stockholders' equity rose from $21,173 million in 2023 to $25,389 million in 2024, an increase of about 19.7%[27] - Proceeds from public offering of common stock amounted to $16,149 million in 2024, contributing positively to financing activities[29] Loss Reduction - Net loss improved from $(22,089) million in 2023 to $(18,914) million in 2024, representing a reduction of about 14%[29] Global Expansion - Activated six new global centers in Q4 2024, totaling 25 new centers for the year, approximately three times the historic activation rate[4]

Core Viewpoint - ClearPoint Neuro, Inc. has received FDA's 510(k) clearance for its ClearPoint Navigation Software Version 3.0, which enhances surgical navigation capabilities in both MRI suites and operating rooms, potentially benefiting over 50 global biopharma partners and standardizing cell and gene therapy delivery in the U.S. [1][2] Company Developments - ClearPoint Navigation Software Version 3.0 introduces an intraoperative CT workflow, expanding its capabilities beyond MRI-guided workflows to include operating room applications [6][7] - The software is compatible with intraoperative CT and Conebeam CT imaging, broadening access to precision-guided neurosurgery for facilities lacking intraoperative MRI capabilities [7] - A limited market release for ClearPoint Navigation Version 3.0 is anticipated in Q1 2025, with a full market release planned for the second half of 2025 [8] Financial Performance - ClearPoint has a market capitalization of $492.4 million, with a Zacks Consensus Estimate indicating a 10.6% year-over-year increase in fiscal 2025 earnings and a 23.4% revenue improvement [5] - The company has delivered an average earnings surprise of 9.84% over the trailing four quarters [5] Stock Performance - Following the announcement of the software clearance, CLPT stock increased by 5.8% to $17.99 in after-market trading [3] - Over the past year, CLPT's shares have risen by 135.1%, significantly outperforming the industry growth of 9% [13] Industry Prospects - The intraoperative CT market is projected to grow at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031, driven by demand for precise surgery, technological advancements, and an increase in chronic disorders [11]

Company Overview - ClearPoint Neuro, Inc. (CLPT) shares increased by 22.5% in the last trading session, closing at $18.42, with notable trading volume compared to typical sessions [1] - The stock has gained 2.8% over the past four weeks [1] Price Target and Investor Sentiment - Lake Street Capital Markets raised ClearPoint Neuro's stock price target to $30.00 from $17.00, maintaining a Buy rating, driven by strong core performance and the potential of its partner business [2] Financial Expectations - The company is expected to report a quarterly loss of $0.15 per share, reflecting a year-over-year change of +21.1% [3] - Revenues are anticipated to be $8.65 million, which is a 27% increase from the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for ClearPoint Neuro has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold) [4] Industry Context - ClearPoint Neuro is part of the Zacks Medical - Instruments industry, which includes other companies like DexCom (DXCM), which saw a 2.3% increase in its last trading session [4] - DexCom's consensus EPS estimate has also remained unchanged, with a year-over-year change of +2% [5]